Series A · Biotech · Espoo, Finland · Founded 2011 · 2–10 employees
Desentum is a Finnish biopharmaceutical company developing breakthrough allergy vaccines that switch immune system responses from hypersensitivity to tolerance using modified hypoallergens. Their lead candidate DM-101PX for birch pollen allergy is in Phase 1 clinical trials in Canada, with promising preliminary safety and efficacy results. The company has raised significant funding including €12M in February 2024 and €8M in January 2022, all led by Springvest Oyj. They are also developing vaccines for peanut and grass pollen allergies, targeting hundreds of millions of allergy sufferers worldwide.
No open roles listed right now.